−3.10USD
−560.85 MUSD
4.18 BUSD
151.68 M
About DAI Nippon Pharmaceutical
Sector
CEO
Hiroshi Nomura
Headquarters
Osaka
Website
Employees (FY)
6.25 K
Founded
1897
ISIN
JP3495000006
FIGI
BBG000DQ1M61
Sumitomo Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of DNPUF is 2.70 USD — it has increased by 4.05% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange DAI Nippon Pharmaceutical stocks are traded under the ticker DNPUF.
DAI Nippon Pharmaceutical is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
DNPUF stock is 3.89% volatile and has beta coefficient of 0.32. Check out the list of the most volatile stocks — is DAI Nippon Pharmaceutical there?
DNPUF earnings for the last quarter are −0.49 USD per share, whereas the estimation was −0.29 USD resulting in a −68.46% surprise. The estimated earnings for the next quarter are −0.41 USD per share. See more details about DAI Nippon Pharmaceutical earnings.
DAI Nippon Pharmaceutical revenue for the last quarter amounts to 514.99 M USD despite the estimated figure of 587.08 M USD. In the next quarter revenue is expected to reach 650.79 M USD.
Yes, you can track DAI Nippon Pharmaceutical financials in yearly and quarterly reports right on TradingView.
DNPUF stock has risen by 12.50% compared to the previous week, the month change is a 12.50% rise, over the last year DAI Nippon Pharmaceutical has showed a 55.67% decrease.
DNPUF net income for the last quarter is −354.12 M USD, while the quarter before that showed −193.24 M USD of net income which accounts for −83.25% change. Track more DAI Nippon Pharmaceutical financial stats to get the full picture.
Today DAI Nippon Pharmaceutical has the market capitalization of 1.03 B, it has decreased by 1.03% over the last week.
Like other stocks, DNPUF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DAI Nippon Pharmaceutical stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 6.25 K employees. See our rating of the largest employees — is DAI Nippon Pharmaceutical on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DAI Nippon Pharmaceutical technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DAI Nippon Pharmaceutical stock shows the sell signal. See more of DAI Nippon Pharmaceutical technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on DAI Nippon Pharmaceutical future price: according to them, DNPUF price has a max estimate of 2.72 USD and a min estimate of 1.62 USD. Read a more detailed DAI Nippon Pharmaceutical forecast: see what analysts think of DAI Nippon Pharmaceutical and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DAI Nippon Pharmaceutical EBITDA is −988.38 M USD, and current EBITDA margin is 9.44%. See more stats in DAI Nippon Pharmaceutical financial statements.